company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3360000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3360000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3360000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2716000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9688000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12404000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9044000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-30000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-30000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9074000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9074000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9074000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9074000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,40342671.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,40342671.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41200000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q2,2010-04-01,2010-06-30,2011-08-04 06:18:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3383000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3383000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3383000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2591000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11023000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13614000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10231000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-31000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-31000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10262000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10262000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10262000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10262000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,40382862.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,40382862.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41000000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 06:14:35+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1143000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1143000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1143000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2673000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9436000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12109000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10966000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-435000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-435000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11401000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11401000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11401000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11401000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42008818.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.27
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42008818.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.27
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42200000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 06:09:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.27
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1354000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1354000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1354000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2946000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10417000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13363000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12009000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-493000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-493000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12502000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12502000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12502000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12502000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42166739.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.3
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42166739.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.3
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41700000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q2,2011-04-01,2011-06-30,2011-08-04 06:18:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.3
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1664000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1664000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1664000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3131000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10751000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13882000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12218000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-516000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-516000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12734000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12734000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12734000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12734000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42211858.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.3
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42211858.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.3
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q3,2011-07-01,2011-09-30,2011-11-03 06:14:35+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.3
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3423000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3423000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3423000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2802000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10860000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13662000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10239000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-504000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-504000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10743000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10743000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10743000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10743000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47197572.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,147000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,147000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,147000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2646000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12066000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14712000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14565000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-486000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-486000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15051000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15051000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15051000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15051000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,56366992.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.27
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,56366992.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.27
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,55700000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q1,2012-01-01,2012-03-31,2012-05-03 06:09:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.27
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2882000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11252000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14134000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14134000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-486000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-486000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14620000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14620000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14620000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14620000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,58500000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,58500000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,57650412.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 06:05:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2796000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11743000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14539000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14539000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-457000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-457000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14996000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14996000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14996000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14996000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,60000000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,60000000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,60661720.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 06:05:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3352000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14351000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17703000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17703000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-420000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-420000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18123000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18123000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18123000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18123000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,59200000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.29
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,59200000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.29
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,59411476.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4187000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17876000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22063000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22063000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-724000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-724000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22787000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22787000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22787000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22787000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69100000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.33
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69100000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.33
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69034823.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q2,2013-04-01,2013-06-30,2013-08-01 06:05:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.33
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4171000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17623000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21794000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21794000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-721000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-721000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22515000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22515000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22515000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22515000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,68200000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.33
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,68200000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.33
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69047161.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2013.0,Q3,2013-07-01,2013-09-30,2013-11-04 06:05:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.33
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3127000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16377000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19504000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19504000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-296000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-296000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19800000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19800000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19800000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19800000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,132000000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,132000000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,132295909.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2015.0,Q2,2015-04-01,2015-06-30,2016-07-20 16:01:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3592000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,-103000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3489000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3489000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,19000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,19000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3470000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3470000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3470000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,-91000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3379000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,169000000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,169000000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,137397015.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2016.0,Q2,2016-04-01,2016-06-30,2016-07-20 16:01:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1695000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4380000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6075000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6075000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,76000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,76000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5999000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5999000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5999000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5999000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,12000000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.5
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,12000000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.5
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11955739.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 06:03:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.5
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1955000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6682000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8637000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8637000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,174000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,100000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,274000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8363000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8363000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8363000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8363000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,12300000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.68
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,12300000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.68
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,12378622.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 06:03:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.68
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1871000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5198000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7069000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7069000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,705000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,705000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6364000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6364000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6364000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6364000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14100000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.45
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14100000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.45
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14127868.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 06:03:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.45
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2717000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5109000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7826000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7826000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1166000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,200000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1366000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6460000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6460000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6460000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6460000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.45
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.45
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14383720.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 06:03:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.45
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5122000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6211000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11333000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11333000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2821000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2821000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8512000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8512000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8512000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8512000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15200000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.56
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15200000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.56
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15307872.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 06:03:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.56
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5583000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8871000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14454000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14454000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2979000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2979000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11475000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11475000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11475000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11475000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14800000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.76
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14800000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.76
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14796712.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.76
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5746000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12373000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18119000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18119000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3039000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3039000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15080000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15080000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15080000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15080000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.98
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.98
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15364465.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 06:03:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.98
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7110000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15594000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22704000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22704000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3005000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3005000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19699000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19699000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19699000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19699000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.28
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.28
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15368986.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 06:03:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.28
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4748000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19447000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24195000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24195000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2766000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2766000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21429000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21429000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21429000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21429000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.39
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.39
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15415096.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 06:03:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.39
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5044000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24910000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29954000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29954000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2214000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2214000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27740000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27740000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27740000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27740000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.8
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15400000.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.8
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15394659.0
Madrigal Pharmaceuticals Inc,MDGL,,0001157601,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.8
